Osamu Nureki
Founder at MODALIS THERAPEUTICS CORPORATION
Net worth: 994 999 $ as of 30/05/2024
Osamu Nureki active positions
| Companies | Position | Start | End |
|---|---|---|---|
| MODALIS THERAPEUTICS CORPORATION | Director/Board Member | 31/12/2015 | - |
| Founder | 31/12/2015 | - | |
Curreio, Inc.
 Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Director/Board Member | 31/10/2019 | - |
| University of Tokyo | Corporate Officer/Principal | 31/03/2008 | - |
Career history of Osamu Nureki
Training of Osamu Nureki
| University of Tokyo | Graduate Degree |
Statistics
International
| Japan | 4 |
Operational
| Director/Board Member | 2 |
| Founder | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| MODALIS THERAPEUTICS CORPORATION | Health Technology |
| Private companies | 1 |
|---|---|
Curreio, Inc.
Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Health Technology |
- Stock Market
- Insiders
- Osamu Nureki
- Experience
